Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 01/09/2015
Chairman 71 15/04/2021
Director/Board Member 59 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 15.15L
+10.00%+5.18%+54.35%+71.20% 6.06TCr
+1.44%+4.06%+22.70%+101.03% 5.55TCr
+3.32%+4.11%+14.82%+75.04% 5.52TCr
+0.46%-2.86%+23.34%+33.77% 4.33TCr
+6.42%+3.20%+21.14%+105.56% 4.04TCr
+2.82%+7.24%+236.59%+801.17% 4.16TCr
-3.79%+19.39%+91.90%+77.13% 3.33TCr
+5.32%+6.04%+20.27%+52.98% 3.23TCr
+5.32%+15.84%-40.93%+342.66% 2.29TCr
Average +3.72%+5.02%+49.35%+184.51% 4.28TCr
Weighted average by Cap. +3.72%+4.06%+51.58%+169.51%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock